• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.

作者信息

Sharp M E, Wallace S M, Hindmarsh K W, Brown M A

出版信息

Eur J Clin Pharmacol. 1981;21(3):243-50. doi: 10.1007/BF00627927.

DOI:10.1007/BF00627927
PMID:6119205
Abstract
摘要

相似文献

1
Acetylator phenotype and serum levels of sulfapyridine in patients with inflammatory bowel disease.
Eur J Clin Pharmacol. 1981;21(3):243-50. doi: 10.1007/BF00627927.
2
[Estimations of the serum levels of sulfapyridine on patients treated with sulfasalazin (author's transl)].
Dtsch Z Verdau Stoffwechselkr. 1982;42(1):14-9.
3
Sulfapyridine metabolites in children with inflammatory bowel disease receiving sulfasalazine.接受柳氮磺胺吡啶治疗的炎症性肠病患儿体内的磺胺吡啶代谢物。
J Pediatr. 1979 Oct;95(4):638-40. doi: 10.1016/s0022-3476(79)80786-6.
4
Acetylation polymorphism of sulfapyridine in patients with ulcerative colitis and Crohn's disease.溃疡性结肠炎和克罗恩病患者中磺胺吡啶的乙酰化多态性
Clin Pharmacol Ther. 1975 Nov;18(5 Pt 1):514-20. doi: 10.1002/cpt1975185part1514.
5
[Determination of sulfapyridine levels in serum--a possibility for the control of dose related therapy with sulfasalazine].[血清中磺胺吡啶水平的测定——控制柳氮磺胺吡啶剂量相关治疗的一种可能性]
Dtsch Z Verdau Stoffwechselkr. 1984;44(6):282-8.
6
Therapeutic efficacy of sulfasalazine and its metabolites in patients with ulcerative colitis and Crohn's disease.柳氮磺胺吡啶及其代谢产物对溃疡性结肠炎和克罗恩病患者的治疗效果。
N Engl J Med. 1980 Dec 25;303(26):1499-502. doi: 10.1056/NEJM198012253032602.
7
Desensitization of patients with inflammatory bowel disease to sulfasalazine.
Am J Med. 1982 Oct;73(4):520-4. doi: 10.1016/0002-9343(82)90330-8.
8
Relationship between the acetylator phenotype, plasma sulfapyridine levels and adverse effects during treatment with salicylazosulfapyridine in patients with chronic bowel diseases.慢性肠道疾病患者使用柳氮磺胺吡啶治疗期间乙酰化表型、血浆磺胺吡啶水平与不良反应之间的关系。
Isr J Med Sci. 1990 Jan;26(1):31-4.
9
Compliance to therapy in patients on a maintenance dose of sulfasalazine.服用维持剂量柳氮磺胺吡啶的患者的治疗依从性。
J Clin Gastroenterol. 1982 Aug;4(4):333-6. doi: 10.1097/00004836-198208000-00008.
10
Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.唾液：对正常志愿者和炎症性肠病患者给予柳氮磺胺吡啶后磺胺吡啶的唾液与血浆浓度关系。
Br J Clin Pharmacol. 1980 Jan;9(1):91-4. doi: 10.1111/j.1365-2125.1980.tb04802.x.

引用本文的文献

1
Genetically determined adverse drug reactions involving metabolism.涉及代谢的基因决定的药物不良反应。
Drug Saf. 1993 Jul;9(1):60-77. doi: 10.2165/00002018-199309010-00006.
2
Survey of the human acetylator polymorphism in spontaneous disorders.自发性疾病中人类乙酰化多态性的调查。
J Med Genet. 1984 Aug;21(4):243-53. doi: 10.1136/jmg.21.4.243.
3
Genetically determined variability in acetylation and oxidation. Therapeutic implications.乙酰化和氧化的基因决定变异性。治疗意义。

本文引用的文献

1
The metabolism of salicylazosulphapyridine in ulcerative colitis: II The relationship between metabolites and the progress of the disease studied in outpatients.柳氮磺胺吡啶在溃疡性结肠炎中的代谢：II 门诊患者中代谢物与疾病进展的关系研究。
Gut. 1973 Aug;14(8):637-41. doi: 10.1136/gut.14.8.637.
2
Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.人体中某些磺胺类药物乙酰化表型及药代动力学的测定
Clin Pharmacokinet. 1980 May-Jun;5(3):274-94. doi: 10.2165/00003088-198005030-00006.
3
Kinetic discrimination of three sulfamethazine acetylation phenotypes.
Drugs. 1985 Apr;29(4):342-75. doi: 10.2165/00003495-198529040-00003.
Clin Pharmacol Ther. 1980 Jan;27(1):104-13. doi: 10.1038/clpt.1980.16.
4
Saliva: plasma concentration relationships for sulphapyridine following sulphasalazine administration to normal volunteers and patients with inflammatory bowel disease.唾液：对正常志愿者和炎症性肠病患者给予柳氮磺胺吡啶后磺胺吡啶的唾液与血浆浓度关系。
Br J Clin Pharmacol. 1980 Jan;9(1):91-4. doi: 10.1111/j.1365-2125.1980.tb04802.x.
5
Absorption, metabolism, and excretion of salicylazosulfapyridine in man.柳氮磺胺吡啶在人体中的吸收、代谢及排泄
Clin Pharmacol Ther. 1972 Jul-Aug;13(4):539-51. doi: 10.1002/cpt1972134539.
6
Acetylator phenotype and adverse effects of sulphasalazine in healthy subjects.健康受试者中乙酰化代谢表型与柳氮磺胺吡啶的不良反应
Gut. 1972 Apr;13(4):278-84. doi: 10.1136/gut.13.4.278.
7
The metabolism of salicylazosulphapyridine in ulcerative colitis. I. The relationship between metabolites and the response to treatment in inpatients.柳氮磺胺吡啶在溃疡性结肠炎中的代谢。I. 住院患者中代谢产物与治疗反应的关系
Gut. 1973 Aug;14(8):631-41. doi: 10.1136/gut.14.8.631.
8
Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype.柳氮磺胺吡啶治疗期间的不良反应及其与药物代谢和乙酰化酶表型的关系。
N Engl J Med. 1973 Sep 6;289(10):491-5. doi: 10.1056/NEJM197309062891001.
9
Screening methods using sulfamethazine for determining acetylator phenotype.使用磺胺二甲嘧啶测定乙酰化酶表型的筛查方法。
Clin Pharmacol Ther. 1979 Dec;26(6):757-65. doi: 10.1002/cpt1979266757.
10
Chronic inflammatory bowel disease in children and adolescents: part I.儿童和青少年慢性炎症性肠病：第一部分
South Med J. 1978 Aug;71(8):935-48. doi: 10.1097/00007611-197808000-00020.